Biologics Commonly Used in Cutaneous Crohn's Disease
Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.
-
By
-
Andrea Surnit
-
May 27, 2026
-
Objective:
To evaluate the outcomes of biologic or small-molecule inhibitor therapy in patients with cutaneous Crohn's disease (CCD).
Key Findings:
- Include the terminal ileum as the most commonly involved gastrointestinal site.
- Add the percentages of patients with no inflammatory bowel disease diagnosis, ulcerative colitis, and indeterminate colitis.
Interpretation:
Remove unsupported conclusions about treatment efficacy and timing.
Limitations:
- Expand on the variability in treatment regimens across patients and centers.
Conclusion:
This study contributes to the limited literature on cutaneous Crohn's disease.
